COVID-19 Vaccine Responses in Patients With Plasma Cell Dyscrasias After Complete Vaccination
완전한 백신 접종 후 형질 세포 이상증 환자의 COVID-19 백신 반응
Article
[키워드] adenoviral vector vaccine
Administered
age
anti-CD38
anti-spike antibodies
anti-spike antibody
antibody
Antibody Response
Antibody responses
Antibody testing
Cell
clinical history
Complete
consecutive patient
consecutive patients
COVID-19
COVID-19 vaccination
detectable
drug therapy
dyscrasia
evaluated
Evidence
evidence of
examined
functional
heterologous mRNA vaccine
Hypogammaglobulinemia
Immunocompromised
increased risk
Infection
IVIG
Johnson & Johnson
Johnson & Johnson
management
Moderna
monoclonal antibody
monoclonal antibody therapy
mRNA vaccine
Multiple
Multiple myeloma
Multivariate analysis
negatively affected
nucleocapsid
Patient
plasma
Plasma cell
Plasma Cell Dyscrasias
Quantitative
receiving
response
responses
Roche
SARS-CoV-2
second dose
serologic
Serologic response
spike
Spike antibody detection
tested
the timing
therapy
Treatment
vaccination
Vaccine
Vaccine boosters.
Vaccines
were excluded
were measured
[DOI] 10.1016/j.clml.2021.11.001 PMC 바로가기 [Article Type] Article
[DOI] 10.1016/j.clml.2021.11.001 PMC 바로가기 [Article Type] Article